Skip to content

The mechanism and clinical empirical study of the regulation of ITA-GATA3 signaling pathway by auricular vagus nerve stimulation in the treatment of chronic insomnia comorbidities dyspepsia in the elderly

The mechanism and clinical empirical study of the regulation of ITA-GATA3 signaling pathway by auricular vagus nerve stimulation in the treatment of chronic insomnia comorbidities dyspepsia in the elderly

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400080630
Enrollment
Unknown
Registered
2024-02-02
Start date
2024-06-01
Completion date
Unknown
Last updated
2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Senile chronic insomnia comorbidities indigestion

Interventions

Treatment Group:Concha auriculae Vagus nerve stimulation and traditional Chinese medicine prescription
Control Group:Traditional Chinese medicine prescription

Sponsors

Sichuan Integrative Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 85 Years

Inclusion criteria

Inclusion criteria: ? Age 60-85 years old, male or female; ? Meet the diagnostic criteria for insomnia, and meet the diagnostic criteria for Rome IV functional dyspepsia; ? In the past 1 year, we have perfected electronic gastroscopy, upper gastrointestinal angiography, blood biochemistry, stool routine, and other auxiliary examinations, which can exclude the symptoms of dyspepsia caused by other diseases, and exclude organic diseases, metabolic or systemic diseases of the digestive system; ? In the past week did not take gastrointestinal motonics, antacids and sleeping pills and other drugs; ? Participants in this study should conform to their true wishes, follow the clinical trial design scheme, and sign their names on the informed consent.

Exclusion criteria

Exclusion criteria: ? Those who do not meet the above inclusion criteria; ? Under 60 years old, or over 85 years old; ? Patients with severe mental diseases and serious cardiovascular and cerebrovascular diseases, liver and kidney function, coagulation insufficiency and other serious system diseases; ? Patients with a history of gastrointestinal surgery or mental illness; ? Patients with insomnia or dyspepsia caused by systemic diseases such as pain, fever, cough, surgery, trauma, etc., and external environmental interference factors; ? Ear skin allergy, damage, ulceration, edema, growth and other patients;

Design outcomes

Primary

MeasureTime frame
Pittsburgh sleep quality index;

Secondary

MeasureTime frame
insomnia severity index; Nepean Dyspepsia Index;short form 36 questionnaire;Inflammatory factor (IL-1) ß IL-4, IL-6, TNF- a Hs CRP, TGF- ß);Neurotransmitters (DA, THS, 5-HT, NE, Glu, GABA);

Countries

China

Contacts

Public ContactHao Zhou

Sichuan Integrative Medicine Hospital

545699817@qq.com+86 155 2077 6259

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026